跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
泰菲乐 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Dabrafenib mesylate capsules
Approved
化学药品
Dabrafenib mesylate capsules
NOVARTIS EUROPHARM LIMITED
🇨🇳 National Medical Products Administration
Approval Date
Dec 18, 2019
Approval ID
7ucivx5Cvh0
Company
NOVARTIS EUROPHARM LIMITED
Type
化学药品
Approval Details
Approval Id
7ucivx5Cvh0
Approval Number
H20190067
Generic Name
甲磺酸达拉非尼胶囊
Generic Name En
Dabrafenib mesylate capsules
Trade Name
泰菲乐
Brand Name
泰菲乐
Drug Type
化学药品
Dosage Form
胶囊剂
Strength
50mg(以C₂₃H₂₀F₃N₅O₂S₂计)
Reg Date
2019-12-18
Expired Date
2024-12-17
Company Name
NOVARTIS EUROPHARM LIMITED
Company Address
Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland
Production Company Name
siegfried barbera, s.l.; novartis pharmaceutical manufacturing llc
Production Company Address
Ronda de Santa Maria,158 08210,Barberà del Vallès Barcelona Spain; Verovskova ulica 57 1000 Ljubljana Slovenia
Company Detail Path
/organization/novartis-europharm-limited
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 18, 2019
Approval ID
7ucivx5Cvh0
Type
化学药品
Back to NMPA Approvals